key: cord-0872658-i3iy8ax9
authors: Myhre, Peder L.; Heck, Siri L.; Skranes, Julia B.; Prebensen, Christian; Jonassen, Christine M.; Berge, Trygve; Mecinaj, Albulena; Melles, Woldegabriel; Einvik, Gunnar; Ingul, Charlotte B.; Tveit, Arnljot; Berdal, Jan Erik; Røsjø, Helge; Lyngbakken, Magnus N.; Omland, Torbjørn
title: Cardiac Pathology 6 Months after Hospitalization for COVID-19 and Association with the Acute Disease Severity: Cardiac MRI 6 months after COVID-19
date: 2021-08-13
journal: Am Heart J
DOI: 10.1016/j.ahj.2021.08.001
sha: e2dc9f1f2081c8524d2535aa033b83316d10aacc
doc_id: 872658
cord_uid: i3iy8ax9

BACKGROUND: COVID-19 may cause myocardial injury and myocarditis, and reports of persistent cardiac pathology after COVID-19 have raised concerns of long-term cardiac consequences. We aimed to assess the presence of abnormal cardiovascular resonance imaging (CMR) findings in patients recovered from moderate-to-severe COVID-19, and its association with markers of disease severity in the acute phase. METHODS: Fifty-eight (49%) survivors from the prospective COVID MECH study, underwent CMR median 175 [IQR 105-217] days after COVID-19 hospitalization. Abnormal CMR was defined as left ventricular ejection fraction (LVEF) <50% or myocardial scar by late gadolinium enhancement. CMR indices were compared to healthy controls (n=32), and to circulating biomarkers measured during the index hospitalization. RESULTS: Abnormal CMR was present in 12 (21%) patients, of whom three were classified with major pathology (scar and LVEF<50% or LVEF<40%). There was no difference in the need of mechanical ventilation, length of hospital stay, and vital signs between patients with versus without abnormal CMR after 6 months. SARS-CoV-2 viremia and concentrations of inflammatory biomarkers were not associated with persistent CMR pathology. Cardiac troponin T and N-terminal pro-B-type natriuretic peptide concentrations on admission, were higher in patients with CMR pathology, but these associations were not significant after adjusting for demographics and established cardiovascular disease. CONCLUSIONS: CMR pathology 6 months after moderate-to-severe COVID-19 was present in 21% of patients and did not correlate with severity of the disease. Cardiovascular biomarkers during COVID-19 were higher in patients with CMR pathology, but with no significant association after adjusting for confounders. TRIAL REGISTRATION: COVID MECH Study ClinicalTrials.gov Identifier: NCT04314232

 CMR 6 months post-COVID-19 revealed 16% with minor and 5% with major cardiac pathology  CMR measurements post-COVID-19 was not different from healthy controls  CMR pathology after 6 months was not associated with the severity of COVID-19  Elevated cardiac biomarkers during COVID-19 associated with CMR pathology.  These associations did not persist when adjusting for demographics and preexisting cardiovascular disease ABSTRACT Background COVID-19 may cause myocardial injury and myocarditis, and reports of persistent cardiac pathology after COVID-19 have raised concerns of long-term cardiac consequences. We aimed to assess the presence of abnormal cardiovascular resonance imaging (CMR) findings in patients recovered from moderate-to-severe COVID-19, and its association with markers of disease severity in the acute phase.

Fifty-eight (49%) survivors from the prospective COVID MECH study, underwent CMR median 175 [IQR 105-217] days after COVID-19 hospitalization. Abnormal CMR was defined as left ventricular ejection fraction (LVEF) <50% or myocardial scar by late gadolinium enhancement. CMR indices were compared to healthy controls (n=32), and to circulating biomarkers measured during the index hospitalization.

Abnormal CMR was present in 12 (21%) patients, of whom three were classified with major pathology (scar and LVEF<50% or LVEF<40%). There was no difference in the need of mechanical ventilation, length of hospital stay, and vital signs between patients with versus without abnormal CMR after 6 months. SARS-CoV-2 viremia and concentrations of inflammatory biomarkers were not associated with persistent CMR pathology. Cardiac troponin T and N-terminal pro-B-type natriuretic peptide concentrations on admission, were higher in patients with CMR pathology, but these associations were not significant after adjusting for demographics and established cardiovascular disease.

Conclusions: CMR pathology 6 months after moderate-to-severe COVID-19 was present in 21% of patients and did not correlate with severity of the disease. Cardiovascular biomarkers during COVID-19 were higher in patients with CMR pathology, but with no significant association after adjusting for confounders. CMR who make up the population in the current study (Suppl. Figure 1 ).

Patients were compared to 32 healthy participants from the prospective, populationbased, age-cohort Akershus Cardiac Examination (ACE) 1950 Study 16 . The controls were normotensive, non-obese non-smokers without known diabetes or cardiovascular disease.

The COVID MECH, COVID CMR and ACE 1950 studies were approved by the Regional Ethics Committee (#20/02873; #20/05884; #2011/1475) and by the institutional Data Protection Officer (#117589; #148701; #12_093). No extramural funding was used to support this work. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper and its final contents.

The CMRs were conducted at Akershus University Hospital between June 24 and November 18 2020 on a 1.5 MRI scanner (Achieva; Philips Medical Systems, Best, The Netherlands).

Short-axis, steady-state-free precession sequences were acquired in contiguous 8 mm short axis slices for assessing ventricular volumes and ejection fraction. T2 STIR images were acquired in 10 mm slices in a single midventricular short axis view and one four and one left ventricular two chamber views. Two-dimensional, phase sensitive inversion recovery LGE imaging in contiguous 10 mm short-axis slices covering the ventricles and three long-axis views for assessing myocardial scarring was performed starting 10 minutes after injection of 0 

Assessment of ventricular volumes and EF and mass was performed on cvi42 according to SCMR guidelines 17 . Trabeculations and papillary muscles were included in the LV volumes.

The presence of scar was assessed on LGE sequences by semiautomatic signal intensity thresholding 5 standard deviations above remote myocardium and categorized as ischemic or non-ischemic. Presence of LGE (myocardial scar) or left ventricular EF (LVEF) <50% were defined as abnormal CMR. These were further classified into major pathology (scar and LVEF<50% or LVEF<40%) and minor pathology (scar and LVEF ≥50% or LVEF 40-49%).

T2 STIR images were visually assessed for focal myocardial and pericardial edema.

Myocardial T1 and T2 relaxation times were measured by conservatively placing regions of interest in the midventricular septum. Areas of LGE and significant artifacts were excluded from the measurements. ECV fraction was calculated as previously described 18 . Myocardial feature tracking strain analyzes was performed on cvi42. Left ventricular longitudinal strain was assessed in three long axis views, and circumferential strain in three short axis slices (basal, midventricular, and apical). Examinations with persisting inadequate tracking after up to two times contour correction were excluded from analysis.

Blood samples were collected at admission and on target day 3 (day 2-5 accepted) during hospitalization and stored at -80°C in a study-specific biobank pending analysis.

Measurements of interleukin-6 (IL-6), procalcitonin, ferritin, cardiac troponin T (cTnT) and 

Values are reported as N (%), median (quartile 1 to quartile 3) or mean ± SD, as appropriate.

Categorical and continuous variables were compared using the chi-square test for binary variables, ANOVA for parametric continuous variables, and the Kruskal-Wallis test for nonparametric continuous variables. Change in biomarker concentrations from hospital admission to day 3 were calculated by subtraction and compared by non-parametric tests. To account for possible confounders between biomarker concentrations and CMR pathology, we performed multivariable logistic and linear regression models that were adjusted for age, sex, race and established CVD (selected a priori), using log-transformed biomarker concentrations. We also adjusted for time from index hospitalization to CMR examination in additional models. All statistical analyses were performed using Stata Software (version 16, Stata Corp., College Station, TX, USA). A two-sided p-value of <0.05 was considered statistically significant.

The 

By protocol, the two patients with CKD did not receive contrast and were accordingly not evaluated for myocardial scar by LGE. Both these patients had no other pathology on CMR (comparable LV and RV structure and function, T1, T2 and strain to those with available

LGE), and were accordingly classified with normal CMR. In addition, one patient had unevaluable LGE sequences due to severe motion artifacts. This patient had reduced LVEF, and was accordingly classified with abnormal CMR.

In total, 12 (21%) patients were classified with abnormal CMR. Among these, three patients had major myocardial pathology: one with both myocardial scar (a combined ischemic/nonischemic scar of 6.5% scar volume) and reduced LVEF (38%): one with LVEF 37% and no scar; and one with LVEF 39% and unavailable LGE-measurements due to unevaluable LGE.

The remaining 9 patients with abnormal CMR were classified with minor pathology on CMR.

One patient had a combined ischemic/non-ischemic scar of 3.0 % scar volume, the other 8 had non-ischemic scars (mean scar volume 2.0±1.1%; range 0.7%-4.2%) and LVEF≥50% (mean 57±6%, range 50%-69%) (Figure 1 ). There were no differences in native T1 or T2 values between patients with and without myocardial pathology by conventional CMR findings.

Pericardial enhancement was not identified in any of the patients.

The CMR measurements were compared to 32 healthy controls using the same CMR equipment, method for analysis and analyst. In addition to being free of cardiovascular comorbidities and established risk factors, the healthy controls were older and more frequently female and of white race compared to the COVID CMR patients (Suppl. Table 2 ).

There were no significant differences in LVEF, RVEF, native T1, native T2, extracellular volume, LV strain and myocardial scar between the COVID patients and healthy controls, although there was a borderline significant higher T1 in COVID patients (mean 1006±31 ms vs 993±29 ms, p=0.05; Suppl. Table 3) .

Patients with abnormal versus normal CMR were older, with more prevalent CVD and chronic pulmonary disease ( Table 1) . Vital signs at admission of the index hospitalization were comparable in patients with and without abnormal CMR, apart from lower temperature in those with abnormal CMR. Disease severity scoring, length of hospital stay and the proportion of patients requiring mechanical ventilation in the ICU were also comparable in patients with and without abnormal CMR (Figure 2) . Clinical characteristics, comorbidities, vital signs during the index hospitalization and hospital outcome stratified by the presence of minor and major pathology on CMR is presented in Suppl. Table 4 . There were no differences in patient reported symptoms during acute COVID-19 and post-COVID-19 by presence of CMR pathology (Suppl. Table 5 ). Cardiac arrhythmias during acute-COVID-19

were more common in patients with CMR pathology after 6 months, while there were no differences in prevalence of arrhythmias from screening post-COVID-19. There was no difference in treatment with hydroxychloroquine between patients with and without abnormal CMR (50% vs 37%, p=0.41, respectively).

Eleven (19%) of patients had severe COVID-19 requiring mechanical ventilation in the ICU.

Only one of these had abnormal CMR (non-ischemic scar and LVEF≥50%). Table 2 displays measurements of LV, RV and LA structure and function, myocardial scar, T1, T2 and strain measurements in patients with severe COVID-19 requiring mechanical ventilation in the ICU and in patients with moderate COVID-19 treated in medical wards. Overall, there were no significant differences in CMR measurements between the two groups 6 months after hospitalization ( Table 2) . [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] ng/L vs 7 [4] [5] [6] [7] [8] [9] [10] [11] ng/L, p=0.003) and NT-proBNP (357 [88-616] ng/L vs 97 ng/L, p=0.013) (Figure 2) . For cTnT, these differences were attenuated when adjusting for demographics (age, sex and race) and CVD (p=0.12), while the association persisted in multivariable models for NT-proBNP (p=0.03). For NT-proBNP this difference was driven by Table 6 ).

Patients with elevated NT-proBNP during hospitalization also had significantly higher CMR markers of myocardial edema (T2) and lower LV ejection fraction, but these associations were attenuated when adjusting for demographics and CVD (Suppl. persisted also in adjusted models (p=0.039; Suppl. Table 8 Figure 2 ).

Among 58 unselected patients hospitalized for COVID-19, cardiac pathology on CMR after 6 months was present in 12 (21%) patients. There were no associations between CMR findings and the need for mechanical ventilation, length-of-stay, severity scorings, inflammatory biomarkers or SARS-CoV-2 viremia during the acute COVID-19 hospitalization. Higher concentrations of the cardiovascular biomarkers cTnT and NT-proBNP during the index hospitalization were associated with a higher prevalence of CMR pathology after 6 months, but this was largely attenuated after adjusting for demographics and established CVD.

Among patients with moderate-to-severe COVID-19, we found a substantially lower prevalence of pathology on CMR than in a Germany study by Puntmann et al 10 and myocardial scar in 54%, of which approximately half was myocarditis-like scar and half ischemic scar 21 . This study found no evidence of diffuse fibrosis (T1) or edema (T2) in the remote myocardium compared to matched controls. In our study, we found a lower proportion of focal myocardial scarring than these studies, and no patients with focal myocardial edema or pericardial enhancement. Also, we found no significant differences in T1 or T2 values, or measures of LV and RV structure and function, between patients with severe COVID-19 (requiring mechanical ventilation) and moderate COVID-19 (requiring hospitalization, but not mechanical ventilation). There were also no clinically meaningful differences in CMR measurements between post-COVID-19 patients and healthy controls.

Native T1 was slightly higher (mean 15 ms) compared to healthy controls, and this association reached borderline statistical significance. Elevated T1 has been demonstrated in the subacute phase of COVID-19, and this modest difference may reflect residual changes, but may also be related to a higher prevalence of CVD and risk factors among the COVID-19.

Possible explanations for the lower prevalence of CMR pathology in our COVID-19 patients may relate to differences in time since the acute infection. Myocardial edema decreases in the weeks and months after myocardial injury 22 . In our study, median time from diagnosis to CMR was 175 days, which is longer than the aforementioned studies. This may suggest regression of post-COVID-19 cardiac pathology with time. Secondly, differences in baseline risk factors may play a role. Although the patients in the German study were younger and free of heart failure and cardiomyopathy, other risk factors for subclinical cardiac remodeling such as smoking, chronic obstructive pulmonary disease and coronary disease were more common.

Also, the proportion of pathological CMR findings in the risk-matched control group was of the German study was high. The cohort in the Chinese study was also young, but with moderate to severe COVID-19 infection, and all patients had cardiac symptoms. Finally, technical CMR differences such as MRI field strength and mapping sequences may potentially explain some of the differences.

During acute COVID-19, patients with elevated cardiac troponin have been reported to have elevated T1, extracellular volume and LGE measurements, in addition to enhanced macrophage numbers in myocardial biopsies 6 . In our study, higher concentrations of cTnT and NT-proBNP on admission were associated with the presence of scar or reduced LVEF on CMR after 6 months, and the highest concentrations were seen in patients classified with major CMR pathology. However, patients with scar or reduced LVEF did not experience a greater increase in concentrations of these cardiovascular biomarkers during the infection.

Moreover, the associations were attenuated when adjusting for demographics and established CVD. Accordingly, we believe this most likely reflects pre-existing subclinical CVD rather than persistent COVID-19-related acute myocardial injury and stress. This is supported by the established link between cTnT and NT-proBNP elevations and subclinical myocardial fibrosis and scar in the general population 23, 24 . There were limited associations between CMR measurements of edema (T2) and elevated cTnT and NT-proBNP during the index hospitalization. Importantly, T2 values has been shown to increase with age 25 , and indeed adjusting for this attenuated the association to these cardiovascular biomarkers. However, the association between elevated cTnT concentrations during hospitalization and higher T2 remained significant after adjusting for demographics and established CVD. This finding may imply that patients with myocardial injury during the acute infection may be at risk of persistent myocardial edema after recovery from the acute COVID-19. Still, there were limited correlations between cTnT and other measures of pathology of CMR. Accordingly, the clinical significance of the association between myocardial injury and persistent myocardial edema is uncertain and requires more research with longer follow-up and clinical outcomes such as incident heart failure.

Greater concentrations of inflammatory biomarkers and the presence of SARS-CoV-2 RNA in plasma (viremia) are associated with increased disease severity in COVID-19 [26] [27] [28] . In our study, we could not identify any association between inflammatory biomarkers or presence of SARS-CoV-2 viremia during acute COVID-19 and pathological findings on CMR after recovery. This supports the notion of limited association between severity of the acute infection, reflected by the inflammatory response, and persistent cardiac pathology. COVID-19 is known to cause an overactive and dysfunctional immune response contributing to disease progression, and our observation suggests that the degree of immune activation does not correlate with persistent cardiac pathology. This is in agreement with an autopsy study that found presence of SARS-CoV-2 in the myocardium to be frequent, but not associated with influx of inflammatory cells into the myocardium or lymphocytic myocarditis 29 .

The study was limited to 49% of survivors from the prospective COVID MECH study.

However, patients who agreed to participate in the COVID CMR follow-up study had comparable characteristics and biomarker trajectories compared to patients not willing to participate. Still, we cannot rule out bias that participants were healthier than non-participants.

Although the classification of minor and major pathology on CMR is clinically relevant, the application of arbitrary cut-offs has obvious limitations. Importantly, our findings were consistent when the CMR variables were analyzed continuously. Three patients were not assessable for focal myocardial scarring. The multivariable regression models may be overfitted due to the number of covariates relative to the number of outcomes. Moreover, the modest sample size increases the risk of Type 2 errors, particularly in the adjusted analysis.

Biomarker measurements from the biobank were not available in all patients (n=5), however we were able to use measurements of cardiovascular biomarkers obtained in clinical routine for these patients. We did not have cardiac imaging from the patients pre-COVID-19, and can therefore not with certainty determine whether the CMR findings were caused by COVID-19

or were pre-existing. The healthy control group was not age-matched as patients were included from a population study of participants all born in 1950, and we did not include a risk factor matched control group.

Our findings from CMR 6 months after COVID-19 contrast with the previously reported high prevalence of myocardial pathology assessed shorter after the acute infection. Although we do not have serial CMR to confirm this, it may suggest regression of cardiac pathology over time. Moreover, we found no association between markers of disease severity during the index hospitalization and pathology on CMR after 6 months, suggesting that pre-existing subclinical myocardial disease may be more important than COVID-19 for the observed CMR pathology. [4 , 9 ] 0.42 ICU admission 10 (21.7%) 1 (8.3%) 0.29 Table 2 Cardiac magnetic resonance imaging measurements of left ventricular (LV) and right ventricular (RV) structure and function, myocardial scar by late gadolinium enhancement, T1 and T2 in COVID-19 patients requiring mechanical ventilation at the ICU and in patients treated at the medical wards Abbreviations: LV = left ventricular; RV = right ventricular; LA = left atrial Table 3 Pathology on CMR after 6 months and concentrations of cardiovascular and inflammatory biomarkers during the index hospitalization for COVID-19. Concentrations were measured at admission and changes in concentrations to day 3. Also presented by presence of SARS-CoV-2 viremia, elevated cTnT and NT-proBNP at any time during the index hospitalization for COVID-19 are reported.

Abbreviations: cTnT = cardiac troponin T; NT-proBNP = N-terminal pro-B-type natriuretic peptide; CRP = C-reactive protein; IL-6= interleukin 6; PCT = procalcitonin; SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus 2 

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives

Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis

Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week

Myocardial Inflammation and Dysfunction in COVID-19-Associated Myocardial Injury

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Established Cardiovascular Biomarkers Provide Limited Prognostic Information in Unselected Patients Hospitalized With COVID-19

Persistent Symptoms in Patients After Acute COVID-19

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection

Myocardial Pathology Evaluation in Athletes With Cardiac Magnetic Resonance (COMPETE CMR)

Evaluation for Myocarditis in Competitive Student Athletes Recovering From Coronavirus Disease 2019 With Cardiac Magnetic Resonance Imaging

Growth Differentiation Factor-15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized with COVID-19

NEWS) 2: Standardising the assessment of acute-illness severity in the NHS

Heart and Brain Interactions--the Akershus Cardiac Examination (ACE) 1950 Study Design

Standardized image interpretation and post-processing in cardiovascular magnetic resonance -2020 update : Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing

Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial

Cardiac Involvement in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging

Mediumterm effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge

Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance

Acute myocarditis presenting as acute coronary syndrome: role of early cardiac magnetic resonance in its diagnosis

High-Sensitive Cardiac Troponin T as an Early Biochemical Signature for Clinical and Subclinical Heart Failure: MESA (Multi-Ethnic Study of Atherosclerosis)

Association of Elevated NT-proBNP With Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis (MESA)

Myocardial T2 mapping reveals age-and sex-related differences in volunteers

Association of inflammatory markers with the severity of COVID-19: A meta-analysis

SARS-CoV-2 viral load is associated with increased disease severity and mortality

SARS-CoV-2 RNA in plasma is associated with ICU admission and mortality in patients hospitalized with COVID-19

Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases

We are grateful for the invaluable contributions by My Svensson MD PhD, Ragnhild Røysland MD PhD, Subaitha Navaruban BSc, Ahmed Meklif MSc, Jannicke Dokken RN, Amyla Abueg RN and Linn Bjørnstad Hagen RN. We also thank Haldor Husby and the Unit of Data Analysis at Akershus University Hospital, Lørenskog, Norway, for help with clinical data acquisition from the data warehouse at Akershus University Hospital.

Dr. Myhre is supported by grants from the South-Eastern Norway Regional Health Authority.The COVID MECH study received assays for measuring interleukin-6, procalcitonin, ferritin, cardiac troponin T and N-terminal pro-B-type natriuretic free of charge from Roche Diagnostics. No extramural funding was directly used to support this work.

We are delighted to learn that it may merit publication in American Heart Journal. We have revised the manuscript according to the excellent suggestions and comments made by the reviewers.The paper is not under consideration elsewhere. None of the paper's contents have been previously published. Author disclosures are explicitly stated in the manuscript text. All authors have read and approved the revised manuscript and meet guidelines for authorship.Thank you for your consideration. We hope you find our revised manuscript of interest for the readers of American Heart Journal.